Company Description
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally.
The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services.
Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.
This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery.
It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name.
The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023.
Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 1937 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 11,500 |
| CEO | Prahlad Singh |
Contact Details
Address: 940 Winter Street Waltham, Massachusetts 02451 United States | |
| Phone | 781 663 6900 |
| Website | revvity.com |
Stock Details
| Ticker Symbol | RVTY |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000031791 |
| CUSIP Number | 714046109 |
| ISIN Number | US7140461093 |
| Employer ID | 04-2052042 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Prahlad R. Singh Ph.D. | Chief Executive Officer, President and Director |
| Maxwell Krakowiak | Senior Vice President and Chief Financial Officer |
| Tajinder S. Vohra | Senior Vice President of Global Operations |
| Joel S. Goldberg | Senior Vice President of Administration, General Counsel and Secretary |
| Miriame Victor | Senior Vice President and Chief Commercial Officer |
| Andrew Okun | Vice President, Chief Accounting Officer and Treasurer |
| Bryan A. Kipp | Senior Vice President of Technology and Licensing |
| Madhuri Hegde FACMG, Ph.D. | Senior Vice President and Chief Scientific Officer |
| Stephen Barr Willoughby | Senior Vice President of Investor Relations and Head of ESG |
| Magali Four | Senior Vice President and Chief People and Culture Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 4, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 2, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 9, 2024 | 144 | Filing |